REG - EKF Diagnostics Hldg - Posting of AR&A & Notice of AGM

EKF Diagnostics HoldingsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb3275Ga&default-theme=true

RNS Number : 3275G  EKF Diagnostics Holdings PLC  28 April 2025

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Posting of Annual Report & Accounts
and
Notice of AGM

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, confirms that the Annual Report and Accounts for the year ended 31
December 2024 ("2024 Annual Report") which includes the Notice of the 2025
Annual General Meeting ("AGM") have now been published on the Company's
website via:

 

https://www.ekfdiagnostics.com/documents-reports.html
(https://www.ekfdiagnostics.com/documents-reports.html)

 

The 2024 Annual Report, the Notice of AGM and details for voting by
proxy have been posted today to shareholders who have requested hard copies.

 

The AGM is to be held at 11:00 am on 20 May 2025 at Harwood Capital LLP, 6
Stratton Street Mayfair, London W1J 8LD and will consider the Resolutions set
out in the Notice of AGM.

 

The Company is providing a facility for shareholders to listen in to the AGM
either online or telephonically (in a non-voting capacity) and there will be
an opportunity for shareholders to ask questions. In order to facilitate the
process, the Directors would request that shareholders register for the
meeting and submit questions in advance, before 11:00 am on Friday, 16 May
2025. To register for dial-in details and to submit any questions please
contact Walbrook PR via email at ekf@walbrookpr.com
(mailto:ekf@walbrookpr.com)  or call +44 (0)20 7933 8780.

 

Proxy voting

EKF Diagnostics Holdings plc is not sending out a Form of Proxy this year with
this Notice of Annual General Meeting.

 

Shareholders are being encouraged to vote online via the Investor Centre app
or by logging on to https://uk.investorcentre.mpms.mufg.com/
(https://uk.investorcentre.mpms.mufg.com/) and following the instructions
given.

 

Shareholders can request a hard copy proxy directly from the Registrars, MUFG
Corporate Markets at shareholderenquiries@cm.mpms.mufg.com
(mailto:shareholderenquiries@cm.mpms.mufg.com) or on Tel: 0371 664 0391. Calls
are charged at the standard geographic rate and will vary by provider. Calls
outside the United Kingdom will be charged at the applicable international
rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public
holidays in England and Wales.

 

 EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Stephen Young, CFO           via Walbrook PR

 Singer Capital Markets (Nominated Adviser & Broker)                                        Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUBAORVVUSUAR